Neurocrine Biosciences (NBIX) Leases (2019 - 2026)

Neurocrine Biosciences has reported Leases for 8 years, with the latest figure at $447.1 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 10.97% year-over-year to $447.1 million; the trailing twelve-month figure through Mar 2026 stood at $447.1 million (down 10.97% YoY), and the FY2025 full-year result was $455.4 million, down 10.6% from the prior year.
• Leases for Q1 2026 stood at $447.1 million, down from $455.4 million in the prior quarter.
• The five-year high for Leases was $509.4 million in Q4 2024, with the low at $80.8 million in Q3 2023.
• Historically, Leases has averaged $263.4 million across 5 years, with a median of $257.3 million in 2024.
• Annual changes were most pronounced in 2024 — Leases surged 220.85% — and 2026, when it dropped 10.97%.
• Neurocrine Biosciences' Leases stood at $87.0 million in 2022, then soared by 128.74% to $199.0 million in 2023, then jumped by 155.98% to $509.4 million in 2024, then declined by 10.6% to $455.4 million in 2025, then decreased by 1.82% to $447.1 million in 2026.
• The last three Leases figures came in at $447.1 million (Q1 2026), $455.4 million (Q4 2025), and $468.9 million (Q3 2025), per Business Quant data.